Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets and Therapy

Volumn 2, Issue 2, 2008, Pages 189-199

  Rudick, Richard A ^a   Panzara, Michael A ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BIOGEN   (United States)

Author keywords

Multiple sclerosis; Natalizumab; 4 integrin antagonist

Indexed keywords

EID: 77953469739     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s1956     Document Type: Review

References (40)

1. Balcer LJ, Galetta SL, Calabresi PA, et al. 2007. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 68:1299-304.
2. Balcer LJ, O'Connor PW, Havrdova E. 2005. The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS. Presented at 18th World Congress of Neurology; November 9; Sydney, Australia.
3. Calabresi PA, Giovannoni G, Confavreux C, et al. 2007. The incidence and significance of anti-natalizumab antibodies. Neurology, 69:1391-403.
4. Clifford DB, Yiannoutsos C, Glickman M, et al. 1999. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology, 52:623-5.
5. Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. 1997. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society.
6. Crowder CD, Gyure KA, Drachenberg CB, et al. 2005. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant, 5:1151-8.
7. Data on file. 2007. Cambridge, MA: Biogen Idec, Inc.
8. ® summary of product characteristics.
9. Ffrench-Constant C. 1994. Pathogenesis of multiple sclerosis. Lancet, 343:271-5.
10. Fisher E, O'Connor PW, Havrdova E. 2006. The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study [abstract]. Mult Scler, 12(suppl 1):S103. Abstract P383.
11. Gold R, Jawad A, Miller DH, et al. 2007. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol, 187:156-8.
12. Havrdova E, Giovannoni G, Hitchinson M, et al. 2007. Natalizumab increases the proportion of patients with multiple sclerosis who are disease free [abstract]. Mult Scler, 13(suppl 2):S170. Abstract P567.
13. IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43:655-61.
14. Jacobs LD, Cookfair DL, Rudick RA, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol, 39:285-94.
15. Johnson KP, Brooks BR, Cohen JA, et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 45:1268-76.
16. Kappos K, Bates D, Hartung H-P, et al. 2007. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol, 6:431-41.
17. Khatri B, Fox R, Koo A, et al. 2007. The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study [abstract]. Mult Scler, 13(Suppl 2): S172. Abstract P576.
18. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med, 353:369-74.
19. Langer-Gould A, Atlas SW, Bollen AW, et al. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med, 353:375-81.
20. Lublin FD, Reingold SC. 1996. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology, 46:907-11.
21. Major EO, Amemiya K, Tornatore CS, et al. 1992. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev, 5:49-73.
22. McDonald WI, Compston A, Edan G, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel in the Diagnosis of Multiple Sclerosis. Ann Neurol, 50:121-7.
23. Miller DH, Soon D, Fernando KT, et al. 2007. MRI outcomes in a placebo- controlled trial of natalizumab in relapsing MS. Neurology, 68:1390-401.
24. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. 2000. Multiple sclerosis. N Engl J Med, 343:938-52.
25. O'Connor PW, Goodman A, Kappos L, et al. 2007 The efficacy of natalizumab monotherapy over 3 years of treatment in patients with relapsing multiple sclerosis. Neurology, 68(Suppl 1):A275. Abstract P06.082.
26. Panzara MA, Belcher G, Kooijmans M, et al. 2007. Use of natalizumab in patients with relapsing multiple sclerosis: updated safety results from TOUCH™ and TYGRIS [abstract]. Mult Scler, 13(Suppl 2):S169. Abstract P565.
27. Phillips JT, Kappos L, O'Connor PW, et al. 2006. The effects of natalizumab monotherapy on multiple measures of disability progression in patients with multiple sclerosis. Presented at 58th Annual Meeting of the American Academy of Neurology; April 4; San Diego, CA.
28. Polman CH, O'Connor PW, Havrdova E, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 354:899-910.
29. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet, 352:1498-504.
30. Rudick RA, Antel JA, Confavreux C, et al. 1997. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol, 42:379-82.
31. Rudick RA, Fisher E, Lee J-C, et al. 1999. Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology, 53:1698-704.
32. Rudick RA, Miller D, Hass S, et al. 2007. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol, 62:335-46.
33. Rudick RA, Stuart WH, Calabresi PA, et al. 2006. Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N Engl J Med, 354:911-23.
34. Schellekens H, Casadevall N. 2004. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol, 251(Suppl 2): II/2-II/9.
35. Shitrit D, Lev N, Bar-Gil-Shitrit A, et al. 2005. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int, 17:658-65.
36. ® [prescribing information]. 2007. Cambridge, MA: Biogen Idec, Inc.
37. US Food and Drug Administration, Center for Drug Evaluation and Research, Peripheral and Central Nervous System (PCNS) Advisory Committee. 2006. Briefing Document: Biogen Idec Biologics Marketing Application STN 125104/15, Natalizumab (Tysabri) for Multiple Sclerosis. Silver Spring, MD: US Department of Health and Human Services.
38. Van Assche G, Van Ranst M, Sciot R, et al. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med, 353:362-8.
39. Ware JE Jr, Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 30:473-483.
40. Yousry TA, Major EO, Ryschkewitsch C, et al. 2006. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med, 354:924-33.